|
參考文獻
Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 1989 ; 264:10388-95
Anttila S, Hukkanen J, Hakkola J, Stjernvall T, Beaune P, Edwards RJ, Boobis AR, Pelkonen O, Raunio H. Expression and localization of CYP3A4 and CYP3A5 in human lung. Am J Respir Cell Mol Biol 1997; 16: 242-9
Beaune PH, Umbenhauer DR, Bork RW, Lloyd RS, Guengerich FP. Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase. Proc Natl Acad Sci U S A 1986; 83: 8064-8
Boobis AR, Edwards RJ, Adams DA, Davies DS. Dissecting the function of cytochrome P450. Br. J. Clin. Pharmacol. 1996; 42: 81-89
Chou FC, Tzeng SJ, Huang JD. Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab. Dispo. 2001; 29: 1205-1209.
Degtyarenko KN, Archakov AI. Molecular evolution of P450 superfamily and P450-containing monooxygenase systems. FEBS Lett1993; 332: 1-8
Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol. Pharmacol. 2001; 59:386-392.
Eeckhoudt SL, Desager JP, Horsmans Y, De Winne AJ, Verbeeck RK. Sensitive assay for midazolam and its metabolite 1’-hydroxymidazolam in human plasma by capillary high-performance liquid chromatography. J. Chromatogr. B 1998; 710: 165-171.
Ekins S, Bravi G, Wikel JH, Wrighton SA Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther 1999; 291:424-33
Finta C, Zaphiropoulos. PG. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 2000; 260: 13-23.
Finta C, Zaphiropoulos. PG. Intergenic mRNA molecules resulting from trans-splicing. J. Biol. Chem.2002; 277: 5882-5890.
Fukuen S, Fukuda T, Maune H, Ikenaga Y, Yamamoto I, Inaba T, Azuma J. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics 2002; 12: 331-334.
Guengerich FP. Cytochrome P450 3A4: Regulation and Role in Drug Metabolism. Annu Rev Pharmacol Toxicol 1999; 39: 1-17
Gonzalez FJ, Schmid BJ, Umeno M, Mcbride OW, Hardwick JP, Meyer UA, Gelboin HV, Idle JR. Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA 1988;7: 79-86
Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994; 47: 1643-53
Gillam EM, Guo Z, Ueng YF, Yamazaki H, Cock I, Reilly PE, Hooper WD, Guengerich FP. Expression of cytochrome P450 3A5 in Escherichia coli:effects of 5' modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch Biochem Biophys 1995; 317: 374-84
Graham SE and Peterson JA. How Similar Are P450s and What Can Their Differences Teach Us? Arch Biochem Biophys 1999; 369: 24-9
Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB, Hall SD. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol. Pharmacol.1996; 50: 52-59.
Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, Kamataki T. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem 1993; 218: 585-95
Huss JM, Wang SI, Astrom A, McQuiddy P, Kasper CB. Dexamethasone responsiveness of a major glucocorticoid-inducible CYP3A gene is mediated by elements unrelated to a glucocorticoid receptor binding motif. Proc Natl Acad Sci USA 1996; 93: 4666-70
Hakkola J, Pelkonen O, Pasanen M, Raunio H. Xenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicity. Crit Rev Toxicol 1998; 28: 35-72
Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmoller J, Halpert JR, Zanger UM, Wojnowski L. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-779.
Ishikawa T. The ATP-dependent glutathione S-conjugate export pump. TIBS 1992; 17: 463-9
Jacolot F, Simon I, Dreano Y, Beaune P, Riche C, Berthou F. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 1991; 41: 1911-9
Jounaidi Y, Guzelian PS, Maurel P, Vilarem MJ. Sequence of the 5'-flanking region of CYP3A5: comparative analysis with CYP3A4 and CYP3A7. Biochem Biophys Res Commun 1994; 205: 1741-7
Jounaidi Y, Hyrailles V, Gervot L, Maurel P. Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? Biochem Biophys Res Commun 1996; 221: 466-70
Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, Watkins PB. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994; 4: 247-59
Kivisto KT, Bookjans G, Fromm MF, Griese EU, Munzel P, Kroemer HK. Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Br J Clin Pharmacol 1996; 42: 387-9
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 2001; 27: 383-391.
Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 1995; 104: 1-8
Lin YS, Dowling ALS, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol. Pharmacol. 2002; 62: 162-172.
Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994; 22: 947-55
Lampen A, Christians U, Bader A, Hackbarth I, Sewing KF. Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine. Pharmacology 1996 ;52: 159-68
Murray GI, Weaver RJ, Paterson PJ, Ewen SW, Melvin WT, Burke MD. Expression of xenobiotic metabolizing enzymes in breast cancer. J Pathol 1993; 169: 347-53
Murray GI, Pritchard S, Melvin WT, Burke MD. Cytochrome P450 CYP3A5 in the human anterior pituitary gland. FEBS Lett 1995; 364: 79-82
Murray GI, Taylor MC, Burke MD, Melvin WT. Enhanced expression of cytochrome P450 in stomach cancer. Br J Cancer 1998; 77: 1040-4
Meyer UA. Overview of Enzymes of Drug Mebabolism. J Pharmacokinet Biopharm 1996; 24: 449-73
Nelson DR and Strobel HW. On the Membrane Topology of Vertebrate Cytochrome P-450 Proteins. J Biol Chem 1988; 263: 6038-50
Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42
Nelson DR. Cytochrome P450 and the Individuality of Species. Arch Biochem Biophys 1999; 369: 1-10
Omura T and Morohashi K. Gene Regulation of Steroidogenesis. J. Steroid Biochem. Molec Biol 1995; 53: 19-25
Omura T. Forty years of cytochrome P450. Biochem Biophys Res Commun 1999; 266: 690-8
Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283: 1552-62
Paulussen A, Lavrijsen K, Bohets H, Hendrickx J, Verhaselt P, Luyten W, Konings F, Armstrong M. Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic acitivity in human. Pharmacogenetic 2000; 10: 415-24
Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90: 1225-9
Spurr NK, Gough AC, Stevenson K, Wolf CR. The human cytochrome P450 CYP3A locus:assignment to chromosome 7q22-qter. Hum Genet 1989; 81: 171-4
Schuetz EG, Schuetz JD, Grogan WM, Naray-Fejes-Toth A, Fejes-Toth G, Raucy J, Guzelian P, Gionela K, Watlington CO. Expression of cytochrome P450 3A in amphibian, rat, and human kidney. Arch Biochem Biophys 1992; 294: 206-14
Schuetz JD, Beach DL, Guzelian PS. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 1994; 4: 11-20
Schuetz JD, Guzelian PS. Isolation of CYP3A5P cDNA from human liver: a reflection of a novel cytochrome P-450 pseudogene. Biochim Biophys Acta 1995; 1261: 161-5
Schuetz JD, Scheutz EG, Thottassery JV, Quezlian PS, Storm S, Sun D. Identification of a Novel Dexometasone Responsive Enhance in the Human and Rat Liver Cells. Mol Pharmacology 1996; 49: 63-72
Schuetz EG, Beck WT, Schuetz JD. Modulators and Substrates of P-glycoprotein and Cytochrome P4503A Coordinately UP-regulate these Proteins in Human Colon Carcinoma Cells. Mol Pharmacology 1996; 49: 311-8
Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez JF, Gelboin HV. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives:enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 1998; 8: 391-401
Spurr NK, Gough AC, Stevenson K, Wolf CR. The human cytochrome P450 CYP3A locus: assignment to chromosome 7q22-qter. Hum. Genet. 1989; 81: 171-174.
Stoilov I, Akarsu AN, Alozie I, Child A, Barsoum-Homsy M, Turacli ME, Or M, Lewis RA, Ozdemir N, Brice G, Aktan SG, Chevrette L, Coca-Prados M, Sarfarazi M. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet 1998; 62: 573-84
Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, Gonzalez FJ. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity. Clinl Pharmacol & Ther 2000; 67: 48-56
Tretiakov VE, Degtyarenko KN, Uvarov VYu, Archakov AI. Secondary structure and membrane topology of cytochrome P450s. Arch Biochem Biophys 1989 Dec; 275: 429-39
Wandel C, Bocker R, Bohrer H, Browne A, Rugheimer E, Martin E. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br. J. Anaesth. 1994; 73: 658-661.
Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman-Sundberg M, Oscarson M. Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43. Biochem. Biophys. Res. Commun. 2001; 281: 1349-1355.
Wrighton SA, Ring BJ, Watkins PB, Vandenbranden M. Identification of a polymorphism expressed member of the human cytochrome P-450Ⅲ family. Mol Pharmacology 1989; 36: 97-105
Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990; 38: 207-13
Wandel C, Bocker R, Bohrer H, Browne A, Rugheimer E, Martin E. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 1994;73: 658-61
Wilkinson GR. Cytochrome P4503A (CYP3A) mebabolism: prediction of in vivo activity in humans. J Pharmacokinet Biopharm 1996; 24: 475-533
Wandel C, Bocker RH, Bohrer H, deVries JX, Hofmann W, Walter K, Kleingeist B, Neff S, Ding R, Walter-Sack I, Martin E. Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally. Drug Metab Dispos 1998; 26: 110-4
Wang H, Dick R, Yin H, Licad-Coles E, Kroetz DL, Szklarz G, Harlow G, Halpert JR, Correia MA. Structure-function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe. Biochemistry 1998; 37: 12536-45
Waxman DJ. P450 gene induction by structurally diverse xenochemicals: Central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 1999; 369: 11-23
Westlind A, Lofberg L, Tindberg N, Anderson TB, and Ingelman- Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5’-upstream regulation region. Biochem Biophys Res Commun 1999; 159: 201-5
Wang RW, Newton DJ, Liu NY, Shou M, Rushmore T, Lu AY. Inhibitory anti-CYP3A4 peptide antibody: mapping of inhibitory epitope and specificity toward other CYP3A isoforms. Drug Metab Dispos 1999; 27: 167-72
Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. Biochem Biophys Res Commun 1999; 259: 201-5
Yang HY, Lee QP, Rettie AE, Juchau MR. Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis. Mol Pharmacol 1994; 46: 922-8
Yamakoshi Y, Kishimoto T, Sugimura K, Kawashima H. Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun 1999; 260: 676-81
Yates CR, Zhang W, Song P, Gaber AO, Honaker MR, Kotb M, Alloway RR, Meibohm DB. Effect of CYP3A5 genotype on cyclosporine disposition: A pilot study. Clin. Pharmacol. Ther 2002; 71: P2
|